Microglial cells in the central nervous system (CNS) are crucial in maintaining a healthy environment for neurons to function properly. However, aberrant microglial cell activation can lead to excessive generation of neurotoxic proinflammatory mediators and neuroinflammation, which represents a contributing factor in a wide spectrum of CNS pathologies, including ischemic stroke, traumatic brain damage, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, psychiatric disorders, autism spectrum disorders, and chronic neuropathic pain. Oxidative stress is a salient and common feature of these conditions and has been strongly implicated in microglial cell activation and neuroinflammation. The transient receptor potential melastatin-related 2 (TRPM2) channel, an oxidative stress-sensitive calcium-permeable cationic channel, is highly expressed in microglial cells. In this review, we examine the recent studies that provide evidence to support an important role for the TRPM2 channel, particularly TRPM2-mediated Ca$^{2+}$ signaling, in mediating microglial cell activation, generation of proinflammatory mediators and neuroinflammation, which are of relevance to CNS pathologies. These findings lead to a growing interest in the TRPM2 channel, a new player in neuroinflammation, as a novel therapeutic target for CNS diseases.

Keywords: TRPM2 channel, microglial cell activation, CNS pathologies, neuroinflammation, proinflammatory mediators

INTRODUCTION

The central nervous system (CNS), which is composed of the brain and spinal cord, is a highly integrated and complex network made up principally by neuronal and glial cells. Neuronal cells or neurons as the working unit of the CNS are specialized to transmit information. Glial cells function more in a supportive capacity to surrounding neurons and, nonetheless, as has been
increasingly recognized, also actively participate in many functional aspects of the CNS through bi-directional and dynamic interactions (Jäkel and Dimou, 2017; Allen and Lyons, 2018; Luca et al., 2018). There are several types of glial cells with different embryonic origins (Menassa and Gomez-Nicola, 2018). Astrocytes, oligodendrocytes, and neural-glial antigen 2-positive cells are derived from neuro-ectoderm that also gives rise to neurons, whereas microglial cells are myeloid-lineage cells originated from mesoderm that generates cells of the blood and immune system. Therefore, microglial cells are privileged to be the immune-competent cells of the CNS, like macrophages in the systemic immune system, and thus are often referred to as CNS-resident macrophages. Under healthy or steady-state conditions, microglial cells exhibit a distinctive morphology characteristic of high ramification with an extensive network of fine processes stemming from a small cell body and a resting phenotype (Saijo and Glass, 2011). Microglial cells can secrete neurotrophic factors [e.g., brain-derived neurotrophic factor (BDNF)] and, using their phagocytic capability, eliminate excessive or dysfunctional synapses and clear apoptotic developing neurons. In this way, microglial cells support neuronal functions, particularly important processes such as neurogenesis and synaptogenesis during brain development and in the adult brain (Marin-Teva et al., 2004; Sierra et al., 2010; Kettenmann et al., 2013; Yirmiya et al., 2015; Kierdorf and Prinz, 2017; Ising and Heneka, 2018; Luca et al., 2018). In addition, microglial cells act as the sentinel of the CNS and unceasingly patrol the surroundings with their fine processes to monitor environmental changes and provide the first defensive mechanism in response to damage and infection. Microglial cells express a repertoire of the so-called pattern recognition receptors (PRRs), with Toll-like receptors (TLRs), and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) being two example groups. PRRs detect danger-associated molecular patterns (DAMPs) released from host cells due to damage or stress or pathogen-associated molecular patterns (PAMPs) generated by invading pathogens (Brubaker et al., 2015; Jäkel et al., 2017). Upon ligation of PRRs by DAMPs and/or PAMPs, microglial cells become activated and, after retracting their processes and taking on a spherical form, adopt an amoeboid morphology, proliferate and migrate to the site of damage or infection, where they remove damaged cells or pathogens via phagocytosis (Hanisch and Kettenmann, 2007). Microglial cells can generate proinflammatory mediators that are instrumental in HEIGHTENING acute immune responses, including chemokines [e.g., C-X-C motif ligand 2 (CXCL2)], cytokines [e.g., interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6], nitric oxide (NO), and reactive oxygen species (ROS). Activated microglial cells can also assume distinctive and anti-inflammatory phenotypes and produce anti-inflammatory cytokines and neurotrophic factors [e.g., IL-10, tissue growth factor (TGF)-β and BDNF] that are important in resolving inflammation and stimulating tissue repair (Wang et al., 2015; Tay et al., 2017; Luca et al., 2018). It is increasingly clear that microglial cells exhibit a high level of heterogeneity in the developing brain and an increase in varied proinflammatory subtypes in the aged, inflamed or neurodegenerative brain (Hammond et al., 2018; Sousa et al., 2018).

It is known that numerous DAMPs are released by cells in the CNS as a result of aging, traumatic damage, chronic psychological stress or neurodegenerative diseases, with ATP being one such well-documented example (Jassam et al., 2017; Wei et al., 2018). It is also well-known that DAMPs are released from degenerating neurons in the brain, such as misfolded amyloid β-peptides (Aβ), α-synuclein, and superoxide dismutase 1 (Glass et al., 2010). These DAMPs are potent inducers of chronic activation or senescence of microglial cells, leading to elevated generation of pro-inflammatory mediators that alters neuronal functions and induces neurotoxicity, a process often referred to as neuroinflammation (Glass et al., 2010; Heneka et al., 2018; Luca et al., 2018). Studies over the past decade have gathered a large body of evidence to support that microglial cells play a key role in mediating neuroinflammation as a significant contributing factor in the progression of aging and a wide spectrum of CNS conditions, including ischemic stroke, traumatic brain damage, Alzheimer’s disease (AD), Parkinson’s disease (AD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), neuropsychiatric disorders [e.g., depression, bipolar disorder (BD), and schizophrenia], autism spectrum disorders (ASD), and neuropathic pain (Glass et al., 2010; Yirmiya et al., 2015; Du et al., 2017; Inoue, 2017; Jassam et al., 2017; Mäki et al., 2017; Ramirez et al., 2017; Salter and Stevens, 2017; Alibhai et al., 2018; Bodnar et al., 2018; Ising and Heneka, 2018; Luca et al., 2018; Shetty et al., 2018; Szepesi et al., 2018; Voet et al., 2018).

Oxidative stress, resulting from excessive ROS generation, impaired antioxidant capacity, or both, is a common and salient feature in aging and the aforementioned CNS diseases. The transient receptor potential melastatin-related 2 (TRPM2) channel is a Ca^{2+}-permeable cationic channel with a high sensitivity to oxidative stress or ROS (Harada et al., 2002; Zhang et al., 2003) and is a member of the large transient receptor potential (TRP) superfamilly (Clapham, 2003). In the systemic immune system, the TRPM2 channel has been recognized as an important molecular mechanism mediating DAMP/PAMP-induced generation of proinflammatory mediators and innate immune responses (Knowles et al., 2013; Syed Mortadza et al., 2015). Expression of the TRPM2 channel is widely distributed in the CNS with a high level in microglial cells. In this article, we focus on the TRPM2 channel in microglial cells and its role in neuroinflammation. We start with a brief introduction of the TRPM2 channel activation followed by a summary of the evidence supporting TRPM2 channel expression in microglial cells. We proceed to describe the studies that show an important role of the TRPM2 channel in microglial cell activation and generation of proinflammatory mediators in response to various DAMPs and PAMPs, and also the current understanding regarding the molecular mechanisms responsible for DAMP/PAMP-induced TRPM2 channel activation and the downstream TRPM2-dependent signaling pathways engaged in microglial cell activation and generation of proinflammatory mediators. We also discuss
the studies using rodent models that demonstrate the role of the TRPM2 channel in microglial cell activation and neuroinflammation in CNS diseases. Finally, we highlight the gaps in our understanding that require further investigation in order to test whether targeting the TRPM2 channel, a new player in neuroinflammation, could represent a neuroprotective approach to tempering the progression of aging or CNS diseases.

**TRPM2 CHANNEL ACTIVATION**

Up to now, it has been established both functionally and structurally that the TRPM2 channel is a ligand-gated Ca\(^{2+}\)-permeable cationic channel activated by intracellular ADP-ribose (ADPR), and that ADPR-induced TRPM2 channel activation displays strong dependence of intracellular Ca\(^{2+}\) (Figure 1A) (Perraud et al., 2001; McHugh et al., 2003; Mei et al., 2006; Tong et al., 2006; Xia et al., 2008; Du et al., 2009; Tóth and Csanády, 2010; Huang et al., 2018; Wang et al., 2018; Zhang et al., 2018). Several ADPR analogs, including ADPR-2′-phosphate, 2′-O-acetyl-ADPR and 2′-deoxy-ADPR, have been shown to gate the TRPM2 channel (Figure 1A) (Grubisha et al., 2006; Toth et al., 2015; Fliegert et al., 2017). Cyclic ADPR (cADPR), nicotinamide adenine dinucleotide (NAD) and other structurally or metabolically ADPR-related compounds were also reported in earlier studies using whole-cell recording to activate the TRPM2 channel (Sano et al., 2001; Kolisek et al., 2005; Beck et al., 2006; Togashi et al., 2006). This notion however has been challenged by more recent studies using the excised inside-out recording to show that application of these compounds to the intracellular face of the TRPM2 channel failed to induce TRPM2 channel activation (Tóth and Csanády, 2010; Tóth et al., 2015).

It is also known that warm temperature (≥35°C) induces TRPM2 channel activation alone or in synergy with other TRPM2 channel activators (Figure 1A), as shown in pancreatic β-cells and macrophages (Togashi et al., 2006; Kashio et al., 2012; Kashio and Tominaga, 2015). In this aspect, recent studies have revealed an important role for the TRPM2 channel in sensory neurons in the peripheral and central nervous systems in detecting non-noxious warmth and regulating body temperature (Song et al., 2016; Tan and McNaughton, 2016).

As introduced above, TRPM2 channels display high sensitivity to activation under oxidative stress or more specifically exposure to elevated levels of ROS, thus gaining increasing recognition for their role in mediating cellular responses to oxidative stress (Jiang et al., 2010; Miller and Zhang, 2011; Takahashi et al., 2011; Knowles et al., 2013; Ru and Yao, 2014; Li et al., 2015, 2017; Syed Mortadza et al., 2015; Yamamoto and Shimizu, 2016). While some earlier studies suggested that ROS such as H\(_2\)O\(_2\) may directly activate the TRPM2 channel, it is now widely accepted that ROS-induced TRPM2 channel activation is indirect and depends on mechanisms that promote an increase in intracellular ADPR level (Jiang et al., 2010). One widely-employed mechanism in many types of mammalian cells is generation of ADPR from NAD by poly(ADPR)-polymerase (PARP), particularly PARP-1, and poly(ADPR)-glycohydrolase (PARG) in the nucleus (Figure 1B). Some evidence exists to suggest that ADPR generation from NAD catalyzed by NADase in the mitochondria also contributes in ROS-induced TRPM2 channel activation (Perraud et al., 2005).

**TRPM2 CHANNEL EXPRESSION IN MICROGLIAL CELLS**

Studies examined TRPM2 channel expression in microglial cells at the mRNA, protein and/or functional levels using reverse transcription-polymerase chain reaction (RT-PCR), immunostaining, western blotting, Ca\(^{2+}\) imaging and/or patch-clamp current recording (Kraft et al., 2004; Fonfria et al., 2006; Lee et al., 2010; Jeong et al., 2017; Syed Mortadza et al., 2017). Kraft et al. (2004) were the first to examine TRPM2 channel expression in cultured rat microglial cells. A high level of TRPM2 mRNA expression was detected, and exposure to H\(_2\)O\(_2\) induced extracellular Ca\(^{2+}\) influx, leading to an increase in intracellular Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_i\)). Furthermore, application of intracellular ADPR opened a cationic conductance with a linear current-voltage (I-V) relationship and a single channel conductance of ~65 pS (Kraft et al., 2004), the key biophysical characteristics of the TRPM2 channels (Jiang et al., 2010). A recent study shows strong TRPM2 mRNA and protein expression and ADPR-induced cationic currents in cultured mouse microglial cells (Jeong et al., 2017). Consistently, exposure to H\(_2\)O\(_2\) (10–300 µM) induced concentration-dependent Ca\(^{2+}\) influx and increase in [Ca\(^{2+}\)]\(_i\) in cultured mouse microglial cells from wild-type (WT) but not TRPM2-knockout (TRPM2-KO) mice (Syed Mortadza et al., 2017). Profiling the TRPM2 mRNA level in numerous human tissues, including the brain and spinal cord, revealed abundant expression and a wide distribution of TRPM2 expression in the CNS (Fonfria et al., 2006). In C13, a human microglial cell line, TRPM2 mRNA transcripts were also readily detected, and exposure to H\(_2\)O\(_2\) induced a robust increase in [Ca\(^{2+}\)]\(_i\). Both the mRNA expression level and H\(_2\)O\(_2\)-induced Ca\(^{2+}\) responses were reduced in C13 cells after treatment with TRPM2-specific antisense oligomers (Fonfria et al., 2006). Furthermore, application of intracellular ADPR or extracellular H\(_2\)O\(_2\) elicited cationic currents that exhibited an almost linear I-V relationship and a wide distribution of TRPM2 expression in the CNS (Fonfria et al., 2006). In C13, a human microglial cell line, TRPM2 mRNA transcripts were also readily detected, and exposure to H\(_2\)O\(_2\) induced a robust increase in [Ca\(^{2+}\)]\(_i\). Both the mRNA expression level and H\(_2\)O\(_2\)-induced Ca\(^{2+}\) responses were reduced in C13 cells after treatment with TRPM2-specific antisense oligomers (Fonfria et al., 2006). Furthermore, application of extracellular ADPR or extracellular H\(_2\)O\(_2\) elicited cationic currents that exhibited an almost linear I-V relationship and a strong sensitivity to inhibition by flufenamic acid (FFA), a TRPM2 channel inhibitor (Figure 1A). In cultured human microglial cells isolated from surgically resected temporal lobe tissues, exposure to H\(_2\)O\(_2\) elicited a strong increase in [Ca\(^{2+}\)]\(_i\) that was inhibited by treatment with clotrimazole (Lee et al., 2010), a TRPM2 channel inhibitor (Figure 1A). These studies have gathered compelling evidence to support TRPM2 channel expression in human and rodent microglial cells as a Ca\(^{2+}\) influx pathway with a significant role in ROS-induced Ca\(^{2+}\) signaling.

Interestingly, an earlier study noted that there were significantly greater H\(_2\)O\(_2\)-induced Ca\(^{2+}\) responses and
FIGURE 1 | Direct and indirect mechanisms inducing TRPM2 channel activation. Summary of the major mechanisms that are responsible for direct (A) or indirect (B) activation of the Ca²⁺-permeable TRPM2 channel on the cell surface that mediates Ca²⁺ influx leading to an increase in intracellular Ca²⁺ concentrations. (A) Intracellular Ca²⁺, ADPR and several ADPR analogs bind to and activate the TRPM2 channel alone or in synergy. Warm temperature can also induce TRPM2 channel activation in a yet not well-defined mechanism. The TRPM2 channel inhibitors used in the studies discussed in this review are shown here, and note that none of these inhibitors are TRPM2-specific. (B) ROS can potently but indirectly induce TRPM2 channel activation, mainly via PARP-1/PARG-mediated ADPR generation from NAD in the nucleus. ADPR, ADP-ribose; ADPR-2′-P, ADPR-2′-phosphate; 2-APB, 2-aminoethyl diphenylborinate; FFA, flufenamic acid; ROS, reactive oxygen species; NAD, nicotinamide adenine dinucleotide; pADPR, poly(ADPR); PARP1, poly(ADPR)-polymerase 1; PARG, poly(ADPR)-glycohydrolase.

more readily detectable H₂O₂-induced currents in cultured rat microglial cells after exposure to H₂O₂ or treatment with lipopolysaccharide (LPS), an endotoxin found in the outer membrane of Gram-negative bacteria and a widely-used PAMP to induce immune cell activation through TLR4 activation (Kraft et al., 2004). TRPM2 mRNA expression was up-regulated in C13 cells after treatment with IL-1β (Fonfria et al., 2006). As we discuss below, exposure to diverse pathological stimuli or conditions can increase TRPM2 channel expression in microglial cells.
An increasing number of studies have, mainly using cultured microglial cells, investigated the role of the TRPM2 channel in microglial cell activation and generation of proinflammatory mediators in response to diverse pathological stimuli. Furthermore, as discussed in detail next, efforts have been made to gain considerable insights into the mechanisms by which the TRPM2 channel is activated by such stimuli and the downstream TRPM2-dependent signaling pathways in microglial cell activation and generation of proinflammatory mediators (Figure 2).

**Generation of TNF-α and IL-6 Resulting From Impaired Antioxidant Capacity**

Glutathione (GSH) is present as one of the important reducing agents in most mammalian tissues including the CNS that equip cells with a non-enzymatic antioxidant capacity (Meister and Anderson, 1983). Glutamatecysteine ligase (or γ-glutamylcysteine synthase) is a rate-limiting step in GSH synthesis and thus D,L-buthionine-S,R-sulfoximine (BSO), an inhibitor of glutamatecysteine ligase, can cause depletion of intracellular GSH and cellular oxidative stress. It has been proposed that a reduction in intracellular GSH with aging increases age-related susceptibility to oxidative stress, which is worsened in many neurodegenerative conditions (Sohal and Weindruch, 1996). A previous study investigated the role of the TRPM2 channel in generating neurotoxic proinflammatory mediators in cultured human microglial cells under BSO-induced oxidative stress (Lee et al., 2010). Exposure to BSO (1–24 h) induced an exposure duration-dependent increase in [Ca\(^{2+}\)]. Exposure to BSO for 2 h was sufficient to activate mitogen-activated protein kinases (MAPK), p38, extracellular signal-regulated kinase (ERK) and Jun-N-terminal kinase (JNK), and furthermore downstream nuclear factor NF-kB. BSO-induced increase in [Ca\(^{2+}\)], and activation of MAPK and NF-kB signaling pathways were significantly suppressed by supplementation with GSH or treatment with clotrimazole. Exposure to BSO (0.1, 0.5 and 1 mM) also induced concentration-dependent release of TNF-α and IL-6 from microglial cells, which was reduced by treatment with TRPM2-specific small interference RNA (siRNA) (Lee et al., 2010). These results suggest that oxidative stress resulting from GSH depletion activates the TRPM2 channel and TRPM2-mediated Ca\(^{2+}\) influx in turn initiates downstream MAPK and NF-kB signaling pathways, leading to generation of TNF-α and IL-6 (Figure 2A).

**LPC-Induced Microglial Cell Activation**

It is known that lysophosphatidylcholine (LPC), an inflammatory phospholipid endogenously generated under physiological and various pathological conditions, can induce extracellular Ca\(^{2+}\)-influx in microglial cells and microglial cell activation (Schilling et al., 2004; Sheikh et al., 2009). A recent study has investigated the role of the TRPM2 channel in LPC-induced Ca\(^{2+}\)-signaling and microglial cell activation in cultured mouse microglial cells (Jeong et al., 2017). Exposure to LPC induced cationic currents as well as an extracellular Ca\(^{2+}\)-dependent increase in [Ca\(^{2+}\)]. LPC exposure also resulted in phosphorylation of p38 (p-p38), an indicator of microglial cell activation. Consistently, intrathecal injection of LPC enhanced expression of ionized calcium binding adapter molecule 1 (Iba1) and CD11 in spinal microglial cells, suggesting microglial cell activation (Jeong et al., 2017). Such LPC-induced *in vitro* or *in vivo* effects in microglial cells were largely prevented by TRPM2-KO (Jeong et al., 2017). These results support a key role for the TRPM2 channel in LPC-induced Ca\(^{2+}\) signaling and activation of downstream p38 MAPK signaling pathways, leading to microglial cell activation (Jeong et al., 2017) (Figure 2B). It remains unclear regarding the mechanisms by which LPC induces TRPM2 channel activation, and the types of proinflammatory mediators that are generated as a result of LPC-induced microglial cell activation. This study has made an interesting observation that the levels of both total and cell surface TRPM2 protein expression was significantly increased in LPC-treated microglial cells but it is not elucidated how such up-regulation of TRPM2 expression and membrane trafficking occurs.

**LPS/IFNγ-Induced Activation of iNOS and Generation of NO**

The TRPM2 channel was shown, in an *in vivo* study discussed below, to play a significant role in mediating spinal microglial cell activation and neuropathic pain (Haraguchi et al., 2012). In this study the authors particularly revealed a role for the TRPM2 channel in cultured microglial cells in the activation of inducible NO synthase (iNOS) and generation of NO after exposure to LPS and IFNγ. A subsequent study by the same group investigated the signaling pathways engaged in LPS/IFNγ-induced TRPM2 channel activation and NO generation (Miyake et al., 2014). LPS/IFNγ exposure evoked extracellular Ca\(^{2+}\) influx to increase [Ca\(^{2+}\)], which was prevented by TRPM2-KO or treatment with miconazole, a TRPM2 channel inhibitor (Figure 1A). Such Ca\(^{2+}\) response was also efficiently inhibited by treatment with diphenyleneiodonium (DPI) and ML-171, inhibitors of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidases (NOXs). LPS/IFNγ-induced NO generation was
also significantly reduced by TRPM2-KO, or by inclusion of 1,2-bis(ω-aminophenoxylethane-Ν,Ν,Ν,Ν-tetraacetatic acid (BAPTA), a Ca^{2+} chelator, to remove extracellular Ca^{2+}. These results support that LPS/IFNγ induce NOX-mediated ROS generation, TRPM2 channel activation and an increase in [Ca^{2+}], leading to NO generation (Figure 2C). Moreover, LPS/IFNγ-induced NO generation was attenuated by treatment with AG17, an inhibitor for Ca^{2+} influx that LPS/IFNγ-induced selective activation of p38 in WT but not TRPM2-KO microglial cells, but indiscriminate activation of ERK in both WT and TRPM2-KO microglial cells. Overall, these results suggest that LPS/IFNγ-induced TRPM2-mediated Ca^{2+} signaling initiates activation of PYK2 and downstream p38/JNK MAPK signaling pathways for activation of iNOS and subsequent NO generation (Figure 2C).

**Aβ42-Induced Microglial Cell Activation and Generation of TNF-α**

A recent in vivo study using the APP/PS1 mouse model of AD, as discussed further below, has disclosed an important role of the TRPM2 channel in Aβ-induced AD pathologies, including microglial cell activation (Ostapchenko et al., 2015). It is well-established that TNF-α contributes to AD and neurodegenerative diseases via direct interaction with its death receptor on neurons as well as induction of microglial cell activation to generate additional neurotoxic mediators (Alam et al., 2016; Jiang et al., 2018). Our recent study has explored the molecular mechanisms responsible for TRPM2 channel activation and TNF-α generation in cultured mouse microglial cells induced by exposure to Aβ42, one of the amyloid-β peptides of high relevance to AD (Syed Mortadza et al., 2018). Exposure to Aβ42 (30–300 nM) induced a concentration-dependent and extracellular Ca^{2+}-dependent increase in [Ca^{2+}]. Aβ42-induced
Ca\textsuperscript{2+} response was strongly suppressed by treatment with 2-APB, a TRPM2 channel inhibitor (Figure 1), or BAPTA-AM as a membrane-permeable and thus intracellular Ca\textsuperscript{2+} chelator, and furthermore by TRPM2-KO. Exposure to A\textbeta 42 induced cellular ROS generation and activation of nuclear PARP-1. Both A\beta42-induced PARP-1 activation and increase in [Ca\textsuperscript{2+}]\textsubscript{i} were suppressed by treatment with PJ34, an inhibitor of PARP enzymes including PARP-1. Furthermore, A\beta42-induced ROS generation, PARP-1 activation and Ca\textsuperscript{2+} responses were inhibited by treatment with chelerythrine, a protein kinase C (PKC) inhibitor, GKT137831, a NOX1/4-selective inhibitor, or Phox-i2, a NOX2 inhibitor as well as the NOX generic inhibitor DPI. These results indicate that A\beta42 activates the TRPM2 channel by inducing PKC/NOX-mediated ROS generation and subsequent PARP-1 activation and generation of ADPR (Figure 2D). A\beta42-induced PARP-1 activation and increase in [Ca\textsuperscript{2+}]\textsubscript{i} were also prevented by treatment with PF431396, a PYK2 inhibitor, or U0126, a MEK/ERK inhibitor. A\beta42-induced PARP-1 activation was significantly reduced but incompletely abolished by TRPM2-KO, and the remaining A\beta42-induced PARP-1 activity in TRPM2-KO microglial cells was prevented by treatment with GKT137831 or Phox-i2 and, in striking contrast, not altered by treatment with PF431396 or U0126. Taken together, these results suggest that A\beta42 stimulates PKC/NOX-mediated ROS generation and PARP-1 activation leading to initial TRPM2 channel activation, and that subsequent TRPM2-mediated Ca\textsuperscript{2+} flux and activation of PYK2, MEK/ERK, and PARP-1 serves as a positive feedback mechanism for further TRPM2 channel activation (Figure 2D). Moreover, exposure to A\beta42 induced noticeable morphological changes in microglial cells and an increase in the expression and release of TNF-\textalpha. A\beta42-induced morphological changes and TNF-\alpha generation were prevented by TRPM2-KO and, moreover, by pharmacological inhibition of the aforementioned signaling pathways responsible for TRPM2 channel activation (Syed Mortadza et al., 2018).

A\beta42-Induced Activation of NLRP3 Inflammasome and Generation of IL-1\textbeta

The nucleotide binding domain-containing leucine-rich repeat protein 3 (NLRP3) is a member of the NOD family of PRRs in the cytosol. In response to damage or infection, NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain, and procaspase-1, via protein-protein interactions, assemble a multi-protein complex often termed as the NLRP3 inflammasome. NLRP3 inflammasome activation is required to activate caspase-1, which in turn cleaves pro-IL-1\textbeta into IL-1\textbeta (Tschopp and Schroder, 2010; Brubaker et al., 2015; Jassam et al., 2017; Song et al., 2017; White et al., 2017). It was shown that genetic inactivation of the NLRP3 inflammasome in APP/PS1 mice reduced IL-1\beta generation by microglial cells, leading to improved spatial memory and attenuation of other AD-related pathological phenotypes (Heneka et al., 2013). In addition, NLRP3 inflammasome inactivation shifted microglial cells toward an anti-inflammatory phenotype that cleared A\beta peptides, thereby resulting in a reduction in amyloid-\beta deposition (Heneka et al., 2013). Therefore, neuroinflammation resulting from NLRP3 inflammasome activation and IL-1\beta generation in microglial cells has emerged as an important factor contributing to AD pathogenesis, inciting an interest in targeting the NLRP3 inflammasome as a therapeutic approach to AD (Heneka et al., 2014; White et al., 2017). It is well-known that NLRP3 inflammasome activation and IL-1\beta generation in immune cells including microglial cells exhibit a striking convergence on ROS generation (Tschopp and Schroder, 2010; Song et al., 2017). A recent pharmacological study has examined the potential role of the TRPM2 channel in A\beta42-induced NLRP3 inflammasome activation and IL-1\beta generation in LPS-primed microglial cells (Aminzadeh et al., 2018). Exposure to A\beta42 at a relatively high concentration (10 \mu M) induced mitochondrial ROS generation and also IL-1\beta generation, both of which were suppressed by treatment with DPI at a high concentration (20 \mu M) that presumably targets mitochondrial ROS generation. A\beta42-induced IL-1\beta generation was inhibited by treatment with VAS2870 or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate, NOX inhibitors, indicating engagement of NOX-mediated ROS generation. In addition, A\beta42-induced IL-1\beta generation was reduced by treatment with N-acetylcysteine, a ROS scavenger, or DPQ, a PARP-1 inhibitor (Aminzadeh et al., 2018). Exposure to A\beta42 resulted in a Ca\textsuperscript{2+} influx-dependent increase in [Ca\textsuperscript{2+}]\textsubscript{i}, that was also strongly inhibited by treatment with DPI, VAS2870, DPQ, or BAPTA-AM. Finally, A\beta42-induced caspase-1 activation, as shown by western blotting, was inhibited by treatment with DPQ or BAPTA-AM (Aminzadeh et al., 2018). These results are consistent with the notion that A\beta42 induces NLRP3 inflammasome activation and IL-1\beta generation via stimulating mitochondrial and NOX-mediated ROS generation, activation of PARP-1 and the TRPM2 channel, and subsequent TRPM2-mediated Ca\textsuperscript{2+} influx (Figure 2E). However, more and definitive evidence is required to corroborate the proposed role of the TRPM2 channel.

TRPM2 CHANNEL IN NEUROINFLAMMATION AND CNS PATHOLOGIES

It is clear from the above discussion that studies based on cultured microglial cells support an important role for the TRPM2 channel in microglial cell activation and generation of neurotoxic proinflammatory mediators in response to DAMPS/PAMPs of high relevance to various CNS diseases. As discussed next, there is increasing evidence from in vivo studies using rodent models that supports a critical role for the TRPM2 channel in microglial cells in microglial cell activation, generation of proinflammatory mediators and neuroinflammation in the pathogenesis of CNS diseases (Figure 3).

Neuropathic Pain

It is well-recognized that microglial cell activation in the spinal cord, as well as peripheral neuroinflammation, plays
a significant role in the development of chronic neuropathic pain (Ji and Suter, 2007; Costigan et al., 2009; Tsuda et al., 2013). The role of the TRPM2 channel in mediating spinal microglial cell activation and neuropathic pain was explored in a previous study using two mouse models of neuropathic pain induced by partial sciatic nerve ligation (SNL) and spinal nerve transection (SNT), respectively (Haraguchi et al., 2012). Both mechanical allodynia and thermal hyperalgesia observed in WT mice during the 2 weeks following SNL were largely absent in TRPM2-KO mice. In the sciatic nerves on the ligation site, the TRPM2 mRNA level was markedly elevated. SNL induced a significant increase in the number of neutrophils and also in generation of CXCL2 in WT mice, both of which were mitigated or completely prevented in TRPM2-KO mice. SNL also resulted in a strong increase in the TRPM2 mRNA expression in dorsal microglial cells and in the intensity of immunoreactivity for both Iba1 and CD11b. Moreover, there was an increase in p-p38 and strong co-localization of p-p38 and CD11b, further indicating microglial cell activation. SNL-induced increase in the intensity of immunoreactivity for Iba1, CD11b and p-p38, and co-localization of p-p38 and CD11b in spinal microglial cells was largely prevented by TRPM2-KO. Similarly, SNT induced mechanical allodynia, increased intensity of immunoreactivity to CD11b and p-p38 and their co-localization in dorsal microglial cells, all of which were significantly subdued in TRPM2-KO mice. The study further examined the role of the TRPM2 channel in the generation of proinflammatory mediators in cultured microglial cells exposed to LPS/IFNγ. LPS/IFNγ stimulated CXCL2 generation and NO release as well as an increase in the mRNA expression of CXCL2, TNF-α, IL-1β, IL-6, and iNOS. LPS/IFNγ-induced generation of CXCL2 and NO, and increased mRNA expression of CXCL2 and iNOS were significantly lowered by TRPM2-KO (Haraguchi et al., 2012). However, the study revealed no significant effect of TRPM2-KO on the mRNA expression of TNF-α, IL-1β and IL-6, indicating engagement of TRPM2-independent mechanisms. These results support the notion that the TRPM2 channel in spinal microglial cells contributes to neuropathic pain by mediating the generation of proinflammatory mediators to aggravate pro-nociceptive inflammatory responses. As discussed above, LPS/IFNγ-induced NO generation depends on TRPM2-mediated Ca2+ signaling and activation of downstream PYK2 and MAPK p38 and JNK signaling pathways (Figure 2C).

Alzheimer's Disease

Alzheimer's disease is an age-related neurodegenerative disease with increasing prevalence in a rapidly aging society, representing the most common cause of dementia that affects tens of millions of older people worldwide. Aβ accumulation is widely thought to be an early and pathogenic event in AD pathogenesis. Oxidative damage is a conspicuous but mechanistically poorly understood feature of AD. As has been recently reviewed (Jiang et al., 2018), studies have shown wide expression of the TRPM2 channel in the brain and strong evidence for the TRPM2 channel as a nexus from Aβ generation and oxidative damage to AD pathologies via multiple cellular and molecular mechanisms, including microglial cell activation. Microglial cells are known to have a dual role in AD (Boche and Nicoll, 2008). They provide a protective role by phagocytic clearance of Aβ, but such a beneficial capacity declines with aging and is overwhelmed by excessive toxic aggregates, becoming inefficient. As introduced above, Aβ can induce chronic activation and senescence of microglial cells leading to excessive generation of ROS and numerous neurotoxic proinflammatory cytokines, such as TNF-α, IL-1β and IL-6, which constitutes a critical component of AD pathogenesis. APP/PS1 mice co-express a chimeric mouse/human amyloid precursor protein (APP) with the Swedish mutations (K670N and M671L) and human presenilin 1 (PS1) with deletion of exon 9 (Jankowsky et al., 2003). A recent study has examined the role of the TRPM2 channel in Aβ-induced AD pathogenesis using this mouse AD model (Ostapchenko et al., 2015). As has been well-documented, the APP/PS1 mice exhibit excessive Aβ generation, amyloid deposits and synaptic loss in the hippocampus and cortex, microglial cell activation, and severe impairment in age-related spatial memory. Genetic deletion of TRPM2 expression in APP/PS1 mice, while resulting in no alteration in amyloid deposition, essentially reversed Aβ-induced synaptic loss, microglial cell activation, and memory impairment (Ostapchenko et al., 2015). These results provide compelling evidence to support a critical role for the TRPM2 channel in Aβ-induced AD-related pathologies. As already discussed above, recent in vitro studies reveal an important role of the TRPM2 channel in mediating Aβ42-induced microglial cell activation and generation of

![Figure 3](https://example.com/figure3.png)
Brain Damage by Deficient Cerebral Blood Circulation

The brain is well-known for its vulnerability to damage by deprivation or restriction of oxygen and/or glucose supply that can occur under conditions such as cerebral ischemic stroke, cardiac arrest, chronic cerebral hypo-perfusion, and neonatal hypoxia-ischemia. Oxidative stress, mainly due to increased ROS generation, is a common characteristic of these conditions. An early study demonstrated elevated TRPM2 mRNA expression in rat brains at 1 and 4 weeks after transient middle cerebral artery occlusion (MCAO), a widely-used rodent model of ischemic stroke (Fonfría et al., 2006). A number of recent studies, using various in vitro and in vivo mouse models of ischemia-reperfusion in conjunction with pharmacological inhibition or genetic deletion of the TRPM2 channel, have supported a critical role of the TRPM2 channel in ischemia-reperfusion brain damage and associated cognitive dysfunction (Jia et al., 2011; Alim et al., 2013; Shimizu et al., 2013, 2016; Gelderblom et al., 2014; Ye et al., 2014). There is also emerging evidence to indicate a role for the TRPM2 channel in mediating brain damage due to hypoxia-ischemia in neonates (Huang et al., 2017) and chronic cerebral hypo-perfusion in adults (Miyanohara et al., 2018).

Of notice, much of the research in this area has so far been devoted to the TRPM2 channel in mediating neuronal death. Nonetheless, there is increasing evidence to suggest a significant contribution of TRPM2-mediated neuroinflammation. For example, selective deletion of the TRPM2 expression in peripheral immune cells substantially protected infarction and cognitive impairment in mice after transient MCAO and reperfusion (Gelderblom et al., 2014). However, the role of the TRPM2 channel in microglial cells in ischemia-reperfusion brain damage largely remains unclear. In the case of neonatal hypoxia-ischemia, a recent study shows that infarction in postnatal day 7 pups, induced by ligation of the right common carotid artery and reducing oxygen supply and examined 24 h or 7 days afterward, was considerably attenuated in heterozygous and homozygous TRPM2-KO pups. In addition, WT pups exhibited sensorimotor dysfunction at 7 days post hypoxia-ischemia, and such deficits were less noticeable in heterozygous and homozygous TRPM2-KO pups. In WT pups, the TRPM2 mRNA expression was greater in the damaged hemisphere than the healthy hemisphere. Hypoxia-ischemia induced a massive increase in the number of glial fibrillary acidic protein (GFAP) positive cells and Iba1-positive cells in WT pups, but not in heterozygous and homozygous TRPM2-KO pups. These results suggest that the TRPM2 channel plays an important role in mediating activation of glial cells, including microglial cells, thereby inducing neonatal hypoxic-ischemic brain damage. The role of the TRPM2 channel in microglial cells has been best understood in brain damage by chronic cerebral hypo-perfusion (Miyanohara et al., 2018). Mice manifested significant white matter damage and cognitive dysfunction 28 days after introduction of bilateral common carotid artery stenosis (BCAS), a model of chronic cerebral hypo-perfusion. At this time point, there was also a significant increase in the TRPM2 mRNA expression and in the level of IL-1β, TNF-α and IL-6 in the corpus callosum. Such BCAS-induced effects, namely, white matter damage, cognitive dysfunction and increased generation of IL-1β, TNF-α and IL-6, were prevented by TRPM2-KO. There was an increase in the number of GFAP positive cells and Iba1-positive cells in the corpus callosum at 14 and 28 days after BCAS, but only the number of Iba1-positive cells was strongly suppressed by TRPM2-KO. The increase in the number of Iba1-positive cells and cognitive dysfunction in BCAS-operated mice was effectively prevented by administration of minocycline, an inhibitor of microglial cell and macrophage activation. Further analysis, using WT and TRPM2-KO mice with bone marrow (BM)-derived cells replaced by WT GFP-labeled BM-derived cells, indicates that the Iba1-positive cells in white matter mainly are largely microglial cells. Collectively, these results therefore support a critical role for the TRPM2 channel in mediating microglial cell activation and generation of proinflammatory cytokines, IL-1β, TNF-α and IL-6, in the aggravation of cognitive impairment by chronic cerebral hypo-perfusion.

SUMMARY AND PERSPECTIVES

In summary, the TRPM2 channel is highly expressed in microglial cells and mainly functions as a plasma membrane Ca2+-permeable cationic channel with a key role in mediating ROS-induced Ca2+ signaling (Figure 1B). In addition, the TRPM2 channel in microglial cells is potently activated by diverse DAMPs and/or PAMPs that induce mitochondrial and/or NOX-mediated ROS generation, activation of PARP-1 and ADPR generation (Figure 2). Studies using rodent models in combination with pharmacological and genetic interventions support a significant role for the TRPM2 channel in microglial cell activation and neuroinflammation in the pathogenesis of various CNS conditions. Currently, this includes neuropathic pain, chronic cerebral hypo-perfusion brain damage, neonatal hypoxia-ischemia and Aβ-induced AD (Figure 3). As mentioned in the introduction, microglial cell-mediated neuroinflammation is a well-recognized factor in the pathogenesis of many other CNS conditions besides the aforementioned conditions. Research has also implicated TRPM2 channel in PD (Sun et al., 2018; An et al., 2019; Li and Jiang, 2019), MS (Tsutsui et al., 2018), traumatic brain damage (Cook et al., 2010; Yüreker et al., 2015), and neurodevelopmental disorders such as ASD (Higashida et al., 2018) and depression (Xu et al., 2006; Jang et al., 2015; Zhong et al., 2016; Ko et al., 2019) as well as ischemic stroke brain damage. Evidently, further research is required to investigate whether the TRPM2 channel in microglial cells in mediating neuroinflammation plays a significant role in these CNS conditions.

As discussed above, recent studies have gained significant insights into the molecular mechanisms by which DAMPs and/or PAMPs induce activation of the TRPM2 channel and generation of diverse proinflammatory mediators that are of strong relevance.
to various CNS diseases. It is clear from the discussion that the current understanding remains fragmented with better insights in some cases than others (Figure 2). Further research is required to provide a coherent understanding of how the TRPM2 channel is activated in response to distinctive stimuli or under different conditions, leading to activation of downstream Ca\(^{2+}\)-signaling pathways, and ultimately how such TRPM2-dependent signaling pathways drive microglial cell activation and generation of proinflammatory mediators.

Given the widespread indication of a significant role for the TRPM2 channel in mediating neuroinflammation and CNS diseases, the TRPM2 channel represents an attractive therapeutic target. The TRPM2 channel also plays important roles in a number of physiological processes, such as insulin release from pancreatic β-cells, regulation of temperature sensation, and peripheral immune responses, which may complicate the concept of targeting TRPM2 as a therapeutic strategy. However, TRPM2 channel expression in the CNS is selectively up-regulated by diverse pathological stimuli or diseased conditions. With continual research into TRPM2 modulation and function in specific cell types, future developments may focus on pharmacological agents that can improve the outcome for patients with CNS diseases while sparing the physiological functions of the channel. Targeting the TRPM2 channel in microglial cells, a newly-emerged player in neuroinflammation, represents an interesting venue of development of promising therapeutics.

**AUTHOR CONTRIBUTIONS**

L-HJ and PM wrote the manuscript. All the authors contributed to literature research and analysis, developed the review topic, and approved the manuscript.

**FUNDING**

This research was supported in part by the Wellcome Trust (072275/Z/03/Z), National Natural Science Foundation of China (31471118), and Alzheimer’s Research Trust (ART/PPG2009A/2 (L-HJ)), a Ph.D. studentship from the Faculty of Biological Sciences of University of Leeds (PM), a Ph.D. scholarship from the Government of Malaysia (SSM), and a Laidlaw Scholarship (JM).

**REFERENCES**

Alam, Q., Alam, M. Z., Mushitaq, G., Damahanouri, G. A., Rasool, M., Kamal, M. A., et al. (2016). Inflammatory process in Alzheimer’s and Parkinson’s diseases: central role of cytokines. Curr. Pharm. Des. 22, 541–548. doi: 10.2174/138161282266151125000300

Alihhi, J. D., Dick, A. B., and Manson, J. C. (2018). Unraveling the giall response in the pathogenesis of Alzheimer’s disease. FASEB J. 32, 5766–5777. doi: 10.1096/fj.20181360R

Alim, I., Teves, L., Li, R., Mori, Y., and Tymianski, M. (2013). Modulation of NMDAR subunit expression by TRPM2 channels regulates neuronal vulnerability to ischemic cell death. J. Neurosci. 33, 17264–17277. doi: 10.1523/JNEUROSCI.17279-13.2013

Allen, N. J., and Lyons, D. A. (2018). Glia as architects of central nervous system formation and function. Science 362, 181–185. doi: 10.1126/science.aat0473

Aminzadeh, M., Roghani, M., Sarfallah, A., and Riazi, G. H. (2018). TRPM2 dependence of ROS-induced NLRP3 activation in Alzheimer’s disease. Int. Immunopharmacol. 54, 75–88. doi: 10.1016/j.intimp.2017.10.024

An, X., Fu, Z., Mai, C., Wang, W., Wei, L., Li, D., et al. (2019). Increasing TRPM2 channel expression in human neuroblastoma SH-SY5Y cells augments the susceptibility to ROS-induced cell death. Cells 8:E28. doi: 10.3390/cells8010028

Beck, A., Kolisek, M., Bagley, L. A., Fleig, A., and Penner, R. (2006). Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. FASEB J. 20, 962–964. doi: 10.1096/fj.05-5538fe

Boche, D., and Nicoll, J. A. (2008). The role of the immune system in clearance of Abeta from the brain. Brain Pathol. 18, 267–278. doi: 10.1111/j.1750-369X.2008.00134.x

Bodnar, C. N., Morganti, J. M., and Bachstetter, A. D. (2018). Depression following Boche, D., and Nicoll, J. A. (2008). The role of the immune system in clearance of Alzheimer’s and Parkinson’s diseases: central role of cytokines. Curr. Pharm. Des. 22, 541–548. doi: 10.2174/138161282266151125000300

Cook, N. L., Vink, R., Helps, S. C., Manavis, J., and Van Den Heuvel, C. (2010). Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol. Neurobiol. 54, 7567–7584. doi: 10.1007/s12035-016-0245-0

Dudley, H., Vanij, P., and Yee, L. (2009). Intracellular calcium activates TRPM2 and its alternative spliced isoforms. Proc. Natl. Acad. Sci. U.S.A. 106, 7239–7244. doi: 10.1073/pnas.0811725106

Du, L., Zhang, Y., Chen, Y., Zhu, J., Yang, Y., and Zhang, H. L. (2017). Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol. Neurobiol. 54, 7567–7584. doi: 10.1007/s12035-016-0245-0

Fliegert, R., Watt, J. M., Schobel, A., Rozewitz, M. D., Moreau, C., Kirchberger, T., et al. (2017). Ligand-induced activation of human TRPM2 requires the terminal ribose of ADPR and involves Arg1433 and Tyr1349. Biochem. J. 474, 2159–2175. doi: 10.1042/BCJ20170991

Foordia, E., Murdock, P. R., Cusdin, F. S., Benham, C. D., Kelsell, R. E., and McNulty, S. (2006). Tissue distribution profiles of the human TRPM cation channel family. J. Recept. Signal Transduct. Res. 26, 159–178. doi: 10.1080/10799890601375006

Gelderblom, M., Melzer, N., Schatting, B., Goh, E., Hicking, G., Arunachalam, P., et al. (2014). Transient receptor potential melatin subfamily member 2 cation channel regulates detrimental immune cell invasion in ischemic stroke. Stroke 45, 3395–3402. doi: 10.1161/STROKEAHA.114.005836

Glass, C. K., Saiko, K., Winner, B., Marchetto, M. C., and Gage, F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918–934. doi: 10.1016/j.cell.2010.02.016

Grubisha, O., Rafti, L. A., Takanishi, C. I., Xu, X., Tong, L., Perraud, A. L., et al. (2006). Metabolite of SIR2 reaction modulates TRPM2 ion channel. J. Biol. Chem. 281, 14057–14065. doi: 10.1074/jbc.M513714200

Hammond, T. R., Robinton, D., and Stevens, B. (2018). Microglia and the brain: complementary partners in development and disease. Annu. Rev. Cell Dev. Biol. 34, 523–544. doi: 10.1146/annurev-cellbio-100616-060509

Hannich, U. K., and Kettenmann, H. (2007). Microglia: active sensor and versatile effectors cells in the normal and pathologic brain. Nat. Neurosci. 10, 1387–1394. doi: 10.1038/nn1997

Hara, Y., Wakamori, M., Ishii, M., Maeno, E., Nishida, M., Yoshida, T., et al. (2002). LTRPC2 Ca\(^{2+}\)-permeable channel activated by changes in redox status confers

Frontiers in Pharmacology | www.frontiersin.org 10 March 2019 | Volume 10 | Article 239
sustainability to cell death. *Mol. Cell* 9, 163–173. doi: 10.1016/S1097-2765(01)00438-5

Haraguchi, K., Kawamoto, A., Isami, K., Maeda, S., Kusano, A., Asakura, K., et al. (2012). TRPM2 contributes to inflammatory and neuropathic pain through the aggravation of pronociceptive inflammatory responses in mice. *J. Neurosci.* 32, 3931–3941. doi: 10.1523/JNEUROSCI.4703-11.2012

Heneka, M. T., Kummer, M. P., and Latz, E. (2014). Innate immune activation in neurodegenerative disease. *Nat. Rev. Immunol.* 14, 463–477. doi: 10.1038/nri3705

Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., et al. (2013). NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. *Nature* 493, 674–678. doi: 10.1038/nature11729

Heneka, M. T., Mcmanus, R. M., and Latz, E. (2018). Inflammomerase signalling in brain function and neurodegenerative disease. *Nat. Rev. Neurosci.* 19, 610–621. doi: 10.1038/s41583-018-0055-7

Higashida, H., Yuih, T., Akther, S., Amina, S., Zhong, J., Liang, M., et al. (2018). TRPM2 channel nexus from oxidative damage to Alzheimer’s pathologies: an emerging novel intervention target for age-related dementia. *Ageing Res. Rev.* 47, 67–79. doi: 10.1016/j.arr.2018.07.002

Jia, J., Verma, S., Nakayama, S., Quillinan, N., Grafe, M. R., Hurn, P. D., et al. (2019). Redox signal-mediated sensitization of transient receptor potential melastatin 2 (TRPM2) to temperature affects macrophage functions. *Proc. Natl. Acad. Sci. U.S.A.* 109, 6745–6750. doi: 10.1073/pnas.1114193109

Kashio, M., and Tominaga, M. (2015). Redox signal-mediated enhancement of the temperature sensitivity of transient receptor potential melastatin 2 (TRPM2) elevates glucose-induced insulin secretion from pancreatic islets. *J. Biol. Chem.* 290, 12435–12442. doi: 10.1074/jbc.M115.649913

Kettenmann, H., Kirchhoff, F., and Verkhratsky, A. (2013). Microglia: new roles for the synaptic stripeter. *Neuron* 77, 10–18. doi: 10.1016/j.neuron.2012.12.023

Kierdorf, K., and Prinz, M. (2017). Microglia in steady state. *J. Clin. Invest.* 127, 3201–3209. doi: 10.1172/JCI90602

Knowles, H., Li, Y., and Perraud, A. L. (2013). The TRPM2 ion channel, an oxidative stress and metabolic sensor regulating innate immunity and inflammation. *ImmunoL. Rev.* 55, 241–248. doi: 10.1007/s12840-012-0373-y

Ko, S. Y., Wang, S. E., Lee, H. K., Jo, S., Han, J., Lee, S. H., et al. (2019). Transient receptor potential melastatin 2 governs stress-induced depressive-like behaviors. *Proc. Natl. Acad. Sci. U.S.A.* 116, 1770–1775. doi: 10.1073/pnas.1814335116

Kolisek, M., Beck, A., Fleig, A., and Penner, R. (2005). Cyclic ADP-ribose and hydrogen peroxide synergize with ADP-ribose in the activation of TRPM2 channels. *Mol. Cell. 18*, 61–69. doi: 10.1016/j.molcel.2005.02.033

Kraft, R., Grimm, C., Grosse, K., Hoffmann, A., Sauерbruch, S., Kettenmann, H., et al. (2011). Hydrogen peroxide and ADP-ribose induce TRPM2-mediated calcium influx and cation currents in microglia. *Am. J. Physiol. Cell Physiol.* 286, C129–C137. doi: 10.1152/ajpcell.00331.2003

Lee, M., Cho, T., Jantaratnoti, N., Wang, Y. T., Megeer, E., and Megeer, P. L. (2010). Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. *FASEB J.* 24, 2533–2545. doi: 10.1096/fj.09-149997

Li, C., Meng, L., Li, X., Li, D., and Jiang, L. H. (2015). Non-NMDAR neuronal Ca2+–permeable channels in delayed neuronal death and as potential therapeutic targets for ischemic brain damage. *Expert Opin. Ther. Targets* 19, 879–892. doi: 10.1517/14728222.2015.1021781

Li, J., Gao, Y., Bao, X., Li, F., Yao, W., Feng, Z., et al. (2017). TRPM2: a potential drug target to retard oxidative stress. *Front. Biosci.* 22:1427–1438.

Li, X., and Jiang, L.-H. (2019). A critical role of the transient receptor potential melastatin 2 channel in a positive feedback mechanism for reactive oxygen species-induced delayed cell death. *J. Cell. Physiol.* 234, 3647–3660. doi: 10.1002/jcp.27134

Luo, A., Calandra, C., and Luca, M. (2018). Molecular bases of Alzheimer’s disease and neurodegeneration: the role of neuroglia. *Aging Dis.* 9, 1134–1152. doi: 10.14336/AD.2018.0201

Matti, P., Mannia, J., and Dunbar, G. L. (2017). Current understanding of the molecular mechanisms in Parkinson’s disease: targets for potential treatments. *Transl. Neurodegener.* 6:28. doi: 10.1186/s40035-017-0089-2

Marin-Teva, J. L., Dusart, I., Colin, C., Gervais, A., Van Rooijen, N., and Mallat, M. (2004). Microglia promote the death of developing Purkinje cells. *Neuron* 41, 535–547. doi: 10.1016/j.neuron.2004.08.006

McHugh, D., Flemming, R., Xu, S. Z., Perraud, A. L., and Beech, D. J. (2017). Critical intracellular Ca2+ dependence of transient receptor potential melastatin 2 (TRPM2) cation channel activation. *J. Biol. Chem.* 278, 11002–11006. doi: 10.1074/jbc.M117020200

Mei, Z. Z., Xia, R., Beech, D. J., and Jiang, L. H. (2006). Intracellular coiled-coil domain engaged in subunit interaction and assembly of melastatin-related transient receptor potential channel 2. *J. Biol. Chem.* 281, 38748–38756. doi: 10.1074/jbc.M607591200

Meister, A., and Anderson, M. E. (1983). Glutathione. *Annu. Rev. Biochem.* 52, 174–182. doi: 10.1146/annurev.bi.52.070183.003431

Menassa, D. A., and Gomez-Nicola, D. (2018). Microglial dynamics during neuroinflammation for the synaptic stripper. *Front. Exp. Neurol.* 3:33. doi: 10.3389/fnexp.2017.00023

Miyake, T., Shirakawa, H., Kusano, A., Sakimoto, S., Konno, M., Nakagawa, T., et al. (2019). TRPM2 contributes to LPS/IFNγ-induced production of nitric oxide via the p38/NIK pathway in microglia. *Biochem. Biophys. Res. Commun.* 444, 212–216. doi: 10.1016/j.bbrc.2014.01.022

Miyahara, I., Kakae, M., Nagayasu, K., Nakagawa, T., Mori, Y., Arai, K., et al. (2018). TRPM2 channel aggravates CNS inflammation and cognitive...
impairment via activation of microglia in chronic cerebral hyperperfusion. *J. Neurosci.* 38, 3520–3533. doi: 10.1523/JNEUROSCI.2451-17.2018

Ostapchenko, V. G., Chen, M., Guzman, M. S., Xie, Y. F., Lavine, N., Fan, J., et al. (2015). The transient receptor potential metabolin 2 (TRPM2) channel contributes to β-amylloid oligomer-related neurotoxicity and memory impairment. *J. Neurosci.* 35, 15157–15169. doi: 10.1523/JNEUROSCI.4081-14.2015

Perraud, A. L., Fleig, A., Dunn, C. A., Bagley, L. A., Lanay, P., Schmitz, C., et al. (2001). ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. *Nature* 411, 595–599. doi: 10.1038/s35079100

Ramirez, A. I., De Hoz, R., Salobrar-Garcia, E., Salazar, J. J., Rojas, B., Ajoy, D., et al. (2005). Accumulation of free ADP-ribose from mitochondria mediates oxidative stress-induced gating of TRPM2 cation channels. *J. Biol. Chem.* 280, 6136–6148. doi: 10.1074/jbc.M411446200

Sierra, A., Encinas, J. M., Deudero, J. J., Chancey, J. H., Enikolopov, G., Overstreet-Wadiche, L. S., et al. (2010). Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. *Cell Stem Cell* 7, 483–495. doi: 10.1016/j.stem.2010.08.014

Shetty, A. K., Kodali, M., Upadhyia, R., and Madhu, L. N. (2018). Emerging anti-inflammaging strategies - scientific basis and efficacy. *J. Pharmacol. Sci.* 135, 15157–15169. doi: 10.1523/JBC.M801049200

Voet, S., Prinz, M., and Van Loo, G. (2018). TRPM2 exacerbates central nervous system inflammation in experimental autoimmune encephalomyelitis by increasing production of CXCL2 chemokines. *J. Neurosci.* 38, 8484–8495. doi: 10.1523/JNEUROSCI.2203-17.2018

White, C. S., Lawrence, C. B., Brough, D., and Rivers-Auty, J. (2017). Lysophosphatidylcholine induces glial cell activation: role of rho kinase. *Sci. Rep.* 7:45032. doi: 10.1038/srep45032

Wang, W. Y., Tan, M. S., Yu, J. T., and Tan, L. (2015). Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. *Ann. Transl. Med.* 3:136. doi: 10.3978/j.issn.2305-5839.2013.03.49

Wei, L., Syed Mortadza, S. A., and Jiang, L. H. (2018). Metastasin-related transient receptor potential 2 channel in Abeta42-induced neuroinflammation: implications to Alzheimer's disease mechanism and development of therapeutics. *Neural Regen. Res.* 13, 419–420. doi: 10.14336/1673-5734.2018.11.005
Ye, M., Yang, W., Ainscough, J. F., Hu, X. P., Li, X., Sedo, A., et al. (2014). TRPM2 channel deficiency prevents delayed cytosolic Zn2+ accumulation and CA1 pyramidal neuronal death after transient global ischemia. Cell Death Dis. 5:e1541. doi: 10.1038/cddis.2014.494

Yirmiya, R., Rimmerman, N., and Reshef, R. (2015). Depression as a microglial disease. Trends Neurosci. 38, 637–658. doi: 10.1016/j.tins.2015.08.001

Yürüker, V., Naziroğlu, M., and Şcenol, N. (2015). Reduction in traumatic brain injury-induced oxidative stress, apoptosis, and calcium entry in rat hippocampus by melatonin: possible involvement of TRPM2 channels. Metab. Brain Dis. 30, 223–231. doi: 10.1007/s11011-014-9623-3

Zhang, W., Chu, X., Tong, Q., Cheung, J. Y., Conrad, K., Masker, K., et al. (2003). A novel TRPM2 isoform inhibits calcium influx and susceptibility to cell death. J. Biol. Chem. 278, 16222–16229. doi: 10.1074/jbc.M300298200

Zhang, Z., Tóth, B., Szollosi, A., Chen, J., and Csanády, L. (2018). Structure of a TRPM2 channel in complex with Ca2+ explains unique gating regulation. eLife 7:e36409. doi: 10.7554/eLife.36409

Zhong, J., Amina, S., Liang, M., Akther, S., Yuhi, T., Nishimura, T., et al. (2016). Cyclic ADP-ribose and heat tegulate oxytocin release via CD38 and TRPM2 in the hypothalamus during social or psychological stress in mice. Front. Neurosci. 10:304. doi: 10.3389/fnins.2016.00304

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Malko, Syed Mortadza, McWilliam and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.